Shares of Marathon Patent Group, Inc. (NASDAQ:MARA) saw unusually-strong trading volume on Friday . Approximately 4,044,850 shares traded hands during trading, an increase of 17% from the previous session’s volume of 3,470,190 shares.The stock last traded at $0.44 and had previously closed at $0.41.

Separately, Zacks Investment Research raised shares of Marathon Patent Group from a “hold” rating to a “buy” rating and set a $0.50 price objective on the stock in a report on Wednesday, May 17th.

The company has a 50 day moving average price of $0.31 and a 200 day moving average price of $0.55. The company’s market cap is $10.55 million.

Marathon Patent Group (NASDAQ:MARA) last released its earnings results on Monday, August 14th. The business services provider reported ($0.09) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.05. Marathon Patent Group had a negative return on equity of 1,139.06% and a negative net margin of 5,770.02%. The firm had revenue of $0.37 million for the quarter, compared to analysts’ expectations of $0.50 million. On average, equities research analysts forecast that Marathon Patent Group, Inc. will post $0.11 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This news story was reported by Daily Political and is the property of of Daily Political. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this news story can be accessed at

Marathon Patent Group Company Profile

Marathon Patent Group Inc (MARA) is engaged in acquiring patents and patent rights from owners or other ventures. The Company monetizes its portfolio of patents and patent rights by entering into license discussions. The Company owns around 378 United States and foreign patents, and patent rights across a range of technologies and markets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.